Metamizol Noridem (Metamizole Sodium Monohydrate)

Metamizole works by non‑selectively inhibiting cyclooxygenase enzymes, which reduces the synthesis of prostaglandins. Lower prostaglandin levels decrease peripheral nociceptor sensitisation and central pain signalling, while also acting on the hypothalamus to lower body temperature.

The specific dose and frequency of Metamizol Noridem are determined by the prescribing clinician based on the patient’s condition, age, weight, and response to therapy. Dosing information is provided on the prescription label.

Safety data for Metamizole during pregnancy and lactation are limited. It should only be used when the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Metamizole is a non‑opioid analgesic that offers rapid pain relief and antipyretic effects, often with a lower risk of gastrointestinal irritation than traditional NSAIDs. However, it carries a rare risk of agranulocytosis, which is less common with many other analgesics, so risk‑benefit assessment is essential.

Metamizol Noridem should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use and discard any solution that appears discoloured or particulate.

Metamizol Noridem is administered by a qualified healthcare professional via intramuscular or intravenous injection. The injection should be given slowly to minimise the risk of hypotension, and the site should be monitored for local reactions.

The most serious adverse reactions include agranulocytosis, severe allergic reactions such as anaphylaxis, and rare skin disorders like Stevens‑Johnson syndrome. Patients should be instructed to seek immediate medical attention if they develop signs of infection, rash, or breathing difficulty.

Metamizol Noridem is contraindicated in individuals with known hypersensitivity to pyrazolones or Metamizole, patients with existing bone‑marrow suppression, and those with severe hepatic or renal impairment where the risk outweighs benefit. It should also be avoided in patients receiving other myelosuppressive therapies.